ClinicalTrials.gg
Active, not recruitingNCT05270044COLUMBUS-ADUpdated Nov 22, 2023

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

A Phase 3 interventional study of Encorafenib and Binimetinib and Placebo to match Encorafenib ; Placebo to match Binimetinib in Melanoma, sponsored by Pierre Fabre Medicament. Active, not recruiting at 155 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
815
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing encorafenib in Melanoma — 4 open to participants now, 8 under way, 2 of them phase 3. encorafenib · Melanoma.

Planned enrollment
2nd of 27
815 · median 35
Started
2022
the only one that year
Phase 3
3 of 27
none open now
Registered
24th of 27
by date
Lead sponsor
2 of 27
Pierre Fabre Medicament

Among the 27 studies testing encorafenib in Melanoma, this one is the 2nd largest by planned enrollment, is the only one that started in 2022, is one of 3 in phase 3, and was the 24th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

4 of the 27 studies testing encorafenib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About encorafenib

encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing encorafenib in Melanoma, or all of them as a file.
02

Study summary

The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard of care (surveillance).

Read the detailed description

This is a randomized triple-blind placebo-controlled international multicenter phase III superiority clinical trial.

Participants with completely resected cutaneous melanoma and documented BRAF V600E/K status by central assay will be randomized 1 to 1 to receive either treatment with encorafenib and binimetinib or their two placebos for 12 months. Patients will be stratified according to the stage of the disease according to AJCC version 8 between:

  • stage IIB (i.e., pT3b or pT4a)
  • stage IIC (i.e., pT4b).

The long-term evaluation of all endpoints (including information about the occurrence of new treatment-related adverse events, if any) will take place 10 years from the randomization of the last patient.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Melanoma
  • Stage II
  • BRAFV600E/K
  • Adjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pre-Screening

  • Male or female ≥ 18 years of age;
  • Surgically resected, with tumour free margins, and histologically/ confirmed new diagnosis of stage II (pT3b-pT4bN0) cutaneous melanomaa;
  • Sentinel node (SN) within 14 weeks from initial diagnosis of melanoma.
  • Sentinel node (SN) staged node negative (pN0);
  • Available tumour sample for central determination of the BRAF V600E/K mutation.

Screening

  • Melanoma confirmed centrally to be BRAF V600E/K mutation-positive;
  • Participant still free of disease as evidenced by the required baseline imaging and physical/dermatological assessments performed respectively within 6 weeks and 2 weeks before randomization (Day 1);
  • No more than 12 weeks elapsed between full surgical resection (including SLNB) and randomization;
  • Recovered from definitive surgery (e.g., complete wound healing, no uncontrolled wound infections or indwelling drains);
  • performance status of 0 or 1;
  • Adequate haematological function as defined as (ANC) ≥ 1.5 x 109/L, ≥ 100 x 109/L and

    ≥ 9.0 g/dL;

  • Adequate renal function as defined as Serum creatinine ≤ 1.5 × ; or calculated ≥ 50 mL/min;
  • Adequate electrolytes, defined as serum potassium and magnesium levels within institutional normal limits;
  • Adequate hepatic function as defined as Serum total ≤ 1.5 x ULN and \< 2 mg/dL, (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x ULN;
  • Adequate cardiac function as defined as ≥ 50% as determined by MUGA scan or echocardiogram and Mean triplicate value ≤ 480 msec and no history of QT syndrome;
  • Adequate coagulation function, defined as ≤1.5× ULN unless the patient is receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range;
  • Negative serum β-HCG test (female patient of only) performed within 3 days prior to Day 1;
  • Female patients of child-bearing potential and male patients must agree to follow the protocol's guidance during the treatment period and for ≥30 days after last administration.

Exclusion criteria

Exclusion Criteria:

Pre-screening

  • Unknown ulceration status;
  • Uveal and mucosal melanoma;
  • Clinically apparent (N+/M1);
  • Microsatellites, satellites and/or in-transit metastases,
  • Local (scar) recurrences.

Screening

  • Breast feeding women;
  • Pregnant women;
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO;
  • History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to randomization;
  • History of previous or concurrent within preceding 3 years or any condition with a of less than 5 years;
  • Participants with a prior cancer associated with RAS mutation;
  • Prior systemic anticancer therapy for melanoma or radiotherapy for melanoma;
  • to the study drugs or to any of the ;
  • Participants with severe lactose intolerance (e.g., Rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption);
  • Impaired cardiovascular function or cardiovascular diseases;
  • Neuromuscular disorders that are associated with CK > (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy);
  • Non-infectious pneumonitis and Interstitial Lung Disease;
  • Positive SARs-CoV-2 or variants of SARs-CoV2 RT-PCR test at screening or suspected to be infected with SARs-CoV2 or variants of SARsCoV2 with confirmation pending;
  • Active bacterial, fungal, or viral infection, including, but not limited to , , and known or AIDS-related illness, or an infection requiring systemic therapeutic treatment within 2 weeks prior to randomization.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
815 participants (estimated)

Study arms

  • Experimental
    Arm A

    Encorafenib and Binimetinib

    Drug: Encorafenib and Binimetinib

  • Placebo comparator
    Arm B

    Placebo to match Encorafenib Placebo to match Binimetinib

    Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib

Interventions

  • DrugEncorafenib and Binimetinib

    Drug pages: Encorafenib · Binimetinib

    Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.

    Also known as: Encorafenib: Braftovi / Binimetinib: Mektovi

  • DrugPlacebo to match Encorafenib ; Placebo to match Binimetinib

    Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival (RFS)

    RFS is defined as the time between the date of randomization and the date of 1) first recurrence (local, regional, or a distant metastasis), 2) new melanoma that is known to be either ulcerated, thick (Breslow thickness\>1 mm) or requiring a treatment other than surgery or 3) death (whatever the cause), whichever occurs first.

    Time frame: Approximately 4.4 years from the accrual of the first patient.

Secondary outcomes

  1. Distant metastasis-free survival (DMFS)

    DMFS is defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first.

    Time frame: Approximately 6.0 years from first patient in

  2. Overall survival (OS)

    OS is defined as time from randomization to the date of death whatever the cause.

    Time frame: Approximately 10 years from first Patient In.

  3. Safety - Incidence, nature, severity and seriousness of treatment emergent adverse events (TEAEs)

    Incidence nature and severity of adverse events and SAEs graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: From the signing of the ICF up to 30 days after end of treatment- approximately 14.5 months

  4. Safety -Incidence, nature and severity of cutaneous malignancies by dermatological examination

    This is to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma, as these have been reported to occur with selective BRAF inhibitor treatment. Incidence, nature and severity of new cutaneous malignancies (kerantoacanthoma, squamous cell carcinoma and new primary melanoma) will be recorded and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: From the signing of ICF to study completion- approximately 10 years from last patient in

  5. Safety -Incidence of Serious adverse events (SAEs)

    Incidence nature and severity of serious adverse events will be recorded and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: From the signing of the ICF to study completion- approximately 10 years from last patient in

  6. Safety and tolerability - Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes in physical examination

    Standard physical examinations on cardiovascular, respiratory, gastrointestinal, dermatological, ophthalmological and neurological systems will be performed and will be evaluated based on normal/abnormal and clinical significance observations. Number of participants with TEAEs related to abnormal or clinical significance observations to the physical examinations after the start of study drug will be reported.

    Time frame: From the signing of the ICF up to 30 days after end of treatment- approximately up to 14.5 months

  7. Safety and tolerability - Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes in vital signs

    Clinically notable elevated values: Systolic blood pressure (BP): ≥ 160 mmHg and an increase ≥ 20 mmHg from baseline; Diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; Heart rate: ≥ 100 beats/min (bpm) with increase from baseline of ≥ 15 bpm; Body temperature \[°C\] ≥ 38°C). Clinically notable low values: Systolic BP: \<120 mmHg with decrease from baseline of ≥ 20 mmHg; Diastolic BP: \< 80 mmHg with decrease from baseline of ≥ 15 mmHg; Heart rate: \<50 bpm with decrease from baseline of ≥ 15 bpm; Body temperature \[°C\]: ≤ 35 °C

    Time frame: From the signing of the ICF up to 30 days after end of treatment- approximately up to 14.5 months

  8. Safety and tolerability : Incidence of TEAEs related to notable changes in clinical safety laboratory parameters from baseline.

    incidence of treatment-emergent adverse events (TEAEs) related to notable changes in clinical safety laboratory parameters from baseline. Number of participants with clinically notable shift from baseline in laboratory parameter values based on national cancer institute common terminology criteria (NCI-CTCAE) grade, Version 5.0 will be graded from Grades 1 to 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death. Clinically notable shift is defined as a worsening from baseline by at least 2 grades, or to grade 3 or above.

    Time frame: From the signing of the ICF up to 30 days after end of treatment- approximately up to 14.5 months

  9. Safety and tolerability -Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of 12-lead electrocardiograms (ECGs)

    12-lead ECGs will be obtained using an internationally recognized 12-lead cardiograph. Clinically notable ECG values: QT \[millisecond (ms)\] and QT interval (ms) corrected for heart rate using Fridericia's formula (QTcF) intervals (ms): increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms.

    Time frame: From the signing of the ICF up to 30 days after end of treatment-approximately up to 14.5 months

  10. Safety and tolerability - Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of echocardiogram or multigated acquisition (ECHO/MUGA) scans.

    ECHO/MUGA scan assess Left Ventricular Ejection Fraction (LVEF). Changes from baseline of LVEF measurements over time will be reported

    Time frame: From the signing of the ICF up to 30 days after end of treatment-approximately up to 14.5 months

  11. Safety and tolerability - Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes in ophtalmic examination

    Changes from baseline and worse value on ophthalmic examination over time will be reported. a full ophthalmic examination by an ophthalmologist will be performed (at baseline an end of treatment) including best corrected visual acuity (BCVA), slit lamp examination, intraocular pressure (IOP), dilatedfundoscopy and optical coherence tomography (OCT). Retinal examination is required to identify findings associated with retinal pigment epithelial detachments (RPED), serous detachment of the retina and RVO (OCT and angiography). the investigator will also monthly monitor visual assesment (general inspection of the eyes, examination of motility and alignment, visual disturbance including diminished central vision, blurred vision or loss of vision).

    Time frame: From the signing of the ICF up to 30 days after end of treatment-approximately up to 14.5 months

  12. Safety and tolerability-Treatment emergent adverse events (TEAEs) leading to dose interruption, reduction and discontinuation.

    Incidence of dose interruptions, dose modifications and discontinuation due to AEs and incidence of AEs requiring additional therapy

    Time frame: On treatment period - 12 months from randomization.

  13. Performance status using the Eastern Co-operative Oncology Group (ECOG) performance status scale.

    Changes from baseline and worse value on Eastern Cooperative Oncology Group (ECOG) Scale with a range from 0 to 5 with lower score mean a lower functional impairment, 5 corresponding to death .

    Time frame: From the signing of the ICF up to 30 days after end of treatment-approximately up to 14.5 months

  14. Patient-reported health-related (HRQoL)-European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) .

    To determine if there is any change from baseline during the treatment and every 6 months thereafter up to 30 months in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire scores. EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system has five dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each is rated according to a five-point verbal rating scale (VRS): 1. no problems, 2. slight problems, 3. moderate problems, 4. severe problems and 5. extreme problems) and translated into a five-digit number that describes the participant's health state

    Time frame: From the signing of the ICF up to 30 months.

  15. Patient-reported health-related (HRQoL)_European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30)

    To determine if there is any change from baseline during the treatment and every 6 months thereafter up to 30 months in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) questionnaire scores EORTC QLQ-C30 consists of fifteen multi-item scales: five functional scales (physical, role, cognitive, emotional and social); nine symptom/items scales (fatigue, pain, nausea, vomiting, dyspnea, insomnia, apetite loss, constipation, diarrhae and financial difficulties) and a global health and Quality of Life (QoL) scale. Each scale in the questionnaire will be scored (0 to 100). High scores represents a high health/quality of life

    Time frame: From the signing of the ICF up to 30 months.

  16. Pharmacokinetic (PK) parameter of encorafenib and its metabolite (LHY746)_Cmin

    Minimum serum concentration (Cmin) will be calculated and reported.

    Time frame: From randomization up to 11 months

  17. Pharmacokinetic (PK) parameter of encorafenib and its metabolite (LHY746)-Cmax

    Maximum serum concentration (Cmax) will be calculated and reported.

    Time frame: From randomization up to 11 months

  18. Pharmacokinetic (PK) parameter of encorafenib and its metabolite (LHY746)_AUC

    Area under the curve (AUC) will be calculated and reported.

    Time frame: From randomization up to 11 months

  19. Pharmacokinetic (PK) parameter of binimetinib and its metabolite (AR00426032)-Cmin

    Minimum serum concentration (Cmin) will be calculated and reported

    Time frame: From randomization up to 11 months

  20. Pharmacokinetic (PK) parameter of binimetinib and its metabolite (AR00426032)-Cmax

    Maximum serum concentration (Cmax) will be calculated and reported.

    Time frame: From randomization up to 11 months

  21. Pharmacokinetic (PK) parameter of binimetinib and its metabolite (AR00426032)-AUC

    Area under the curve (AUC) will be calculated and reported.

    Time frame: From randomization up to 11 months

07

Study locations

155 sites

Showing the first 100 of 155 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Access to de-identified patient-level data in response to scientifically valid research proposals will be provided 30 days after CHMP opinion. All requests from qualified researchers for access to Columbus AD clinical data and information will be managed through a dedicated Pierre Fabre portal.

Supporting information: Study protocol, Informed consent form

Time frame: Study protocol/Informed Consent Form will be made available in Clinical Trial.gov 30 days after the time of CHMP opinion or up to a maximum of 1 year after the end of the trial whichever is earlier. CSR and SAP: 30 days after the time of CHMP opinion or up to a maximum of 1 year after the end of the trial whichever is earlier.

Access criteria: Pierre Fabre corporate portal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Mar 2027, 58 months after the start.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's planned 58 months is above that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Mar 8, 2022
StartActual
May 2, 2022
Primary completionEst.
Mar 31, 2027
CompletionEst.
May 2, 2035
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05270044
Responsible party
Sponsor
First posted
Mar 8, 2022
Start date
May 2, 2022
Primary completion
Mar 31, 2027 (estimated)
Completion
May 2, 2035 (estimated)
Last update
Nov 22, 2023

Study contacts

Alexander C.J. van AKKOOI, MD, PhD
study chair · European Organisation for Research and Treatment of Cancer - EORTC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Encorafenib · Binimetinib

Start the discussion